Side Effects of antipyrine-benzocaine otic: A Synthesis of Findings from 2 Studies

  1. Home
  2. Side Effects of antipyrine-benzocaine otic
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of antipyrine-benzocaine otic: A Synthesis of Findings from 2 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of antipyrine-benzocaine otic: A Synthesis of Findings from 2 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Study Findings

Two studies investigated the side effects of hormone therapy for prostate cancer. 1 found that abiraterone and enzalutamide, common hormone therapies, can cause side effects that affect health-related quality of life (HRQoL). Another study, 2 , focused on testosterone suppression, a standard treatment for advanced prostate cancer. It highlighted side effects like sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk, all of which negatively impact quality of life. The researchers hypothesized that combining abiraterone acetate with prednisone (AAP) and apalutamide could potentially be an effective hormonal therapy while minimizing these side effects.

Reasons for Side Effects

These side effects are thought to occur because these medications block the action of testosterone, a male hormone, to prevent prostate cancer growth.

Common Side Effects

Sexual Dysfunction

Hormone therapies like abiraterone and enzalutamide, as mentioned in 1 and 2 , can lead to sexual dysfunction, such as erectile dysfunction and ejaculatory problems, by suppressing testosterone production.

Osteoporosis

2 highlights that testosterone is crucial for bone health, and its reduction through hormone therapy can lower bone density, increasing fracture risk.

Weight Gain

2 suggests that hormone therapies can contribute to weight gain due to increased appetite and changes in metabolism.

Increased Cardiovascular Risk

2 suggests that hormone therapies might be linked to an elevated risk of cardiovascular problems.

Side Effect Management

Sexual Dysfunction

Addressing sexual dysfunction requires consulting a doctor. There are various treatment options like medication and counseling.

Osteoporosis

Preventing osteoporosis involves consuming calcium and vitamin D, and engaging in regular exercise. If needed, a doctor may prescribe osteoporosis medication.

Weight Gain

Managing weight gain can be achieved through dietary changes and exercise. Consult with a doctor or nutritionist for personalized advice.

Increased Cardiovascular Risk

Minimizing cardiovascular risk involves adopting a healthy lifestyle, including quitting smoking, regular exercise, a balanced diet, and maintaining a healthy weight.

Comparison Between Studies

Similarities

Both studies point to the fact that hormone therapies, like abiraterone and enzalutamide, are effective in controlling prostate cancer growth but can lead to side effects that affect HRQoL.

Differences

1 focused on comparing the impact of abiraterone and enzalutamide on HRQoL, while 2 evaluated the effectiveness and side effects of a combined treatment with abiraterone acetate and apalutamide.

Implications for Real Life

It's crucial to understand that prostate cancer hormone therapies carry the risk of side effects. If you have concerns about potential side effects, discuss them with your doctor and explore appropriate management strategies.

Limitations of Current Research

Both studies emphasize the need for further research to better understand the effectiveness and safety of specific medications and treatments.

Future Research Directions

Future research should focus on developing new therapies and preventive measures to minimize hormone therapy side effects. Additionally, more research is needed to accurately predict the risk of side effects.

Conclusion

Prostate cancer hormone therapies are effective treatment options, but they do come with side effect risks. These studies provide valuable information to help understand and manage these side effects.

Literature analysis of 2 papers
Positive Content
2
Neutral Content
0
Negative Content
0
Article Type
2
0
0
0
2
1.

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.

Author: KhalafDaniel J, SunderlandKatherine, EiglBernhard J, KollmannsbergerChristian K, IvanovNikita, FinchDaygen L, OjaConrad, VergidisJoanna, ZulfiqarMuhammad, GleaveMartin E, ChiKim N

HRQoL improvement

Abiraterone was associated with better patient-reported health-related quality of life (HRQoL) and depression symptoms compared to enzalutamide. The study found that differences in the total FACT-P scores were seen only in the elderly patient subgroup.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.

Author: WerutskyGustavo, MalufFernando Cotait, CronembergerEduardo Henrique, Carrera SouzaVinicius, Dos Santos MartinsSuelen Patricia, PeixotoFábio, SmaletzOren, SchutzFábio, HerchenhornDaniel, SantosTelma, Mavignier CarcanoFlavio, Queiroz MunizDavid, Nunes FilhoPaulo R S, ZaffaroniFacundo, BarriosCarlos, FayAndré

Prostate cancer treatment
Side effects

This study explores the potential of abiraterone acetate with prednisone (AAP) and apalutamide, both alone and in combination, as hormonal therapies for advanced prostate cancer. The researchers hypothesize that these treatments may be effective in reducing castration-associated side effects, such as sexual dysfunction, osteoporosis, weight gain, and increased cardiovascular risk.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.